MedPath

SmartRisk Stroke Prediction by MRI of Carotid Disease

Conditions
Atherosclerotic Disease, Carotid
Registration Number
NCT00860184
Lead Sponsor
VPDiagnostics
Brief Summary

Atherosclerotic plaque at the carotid artery bifurcation is a major source of stroke. The purpose of this investigation is to determine the ability of the SmartRisk software module to predict stroke or stroke-related events due to carotid plaque within a high-risk population. The SmartRisk software module operates on magnetic resonance images (MRI) of the carotid artery wall.

Detailed Description

Carotid artery disease (atherosclerosis) is a major cause of stroke that can be treated with carotid endarterectomy surgery (CEA) or stenting. Subjects with moderate, asymptomatic stenosis (50-79% narrowing) typically do not undergo intervention because the procedural risks outweigh the benefits. However, some of these individuals will have vulnerable plaque that places them at high risk of stroke, but current diagnostic techniques for vulnerable plaque are lacking. Recently, VPDiagnostics developed a new module - SmartRisk - that stratifies risk of stroke for stenotic (50-79% blockage) atherosclerotic plaque. The SmartRisk module uses MRI data to compute a risk assessment from a specific atherosclerotic plaque. A continuous risk value is generated and patients with risk values above a prespecified threshold are at elevated risk for cerebrovascular events arising from carotid artery disease. The purpose of this trial is to determine whether the SmartRisk module is effective at stratifying risk of a carotid-related cerebrovascular event in subjects with asymptomatic 50-79% carotid stenosis.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
300
Inclusion Criteria
  • 50-79% stenosis of the carotid artery
  • age 18 or older
  • no ischemic neurovascular symptoms within preceding 6 months
Exclusion Criteria
  • contraindication to MRI (e.g. weight > 130 kg, pregnancy)
  • prior or planned carotid endarterectomy or stenting
  • history of atrial fibrillation
  • prior neck irradiation

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
stroke or other cerebrovascular symptom (e.g. TIA)18 month mean follow-up at 6 month intervals
Secondary Outcome Measures
NameTimeMethod
any cardiovascular event (e.g. MI)18 month mean follow-up at 6 month intervals

Trial Locations

Locations (15)

New York University School of Medicine

๐Ÿ‡บ๐Ÿ‡ธ

New York, New York, United States

Gotham Cardiovascular Research PC

๐Ÿ‡บ๐Ÿ‡ธ

New York, New York, United States

Michigan State University

๐Ÿ‡บ๐Ÿ‡ธ

East Lansing, Michigan, United States

Cedars-Sinai Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Los Angeles, California, United States

University of California San Francisco

๐Ÿ‡บ๐Ÿ‡ธ

San Francisco, California, United States

Baylor College of Medicine

๐Ÿ‡บ๐Ÿ‡ธ

Houston, Texas, United States

Carl T. Hayden Medical Research Foundation

๐Ÿ‡บ๐Ÿ‡ธ

Phoenix, Arizona, United States

Tufts Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Boston, Massachusetts, United States

Western Institute for Biomedical Research

๐Ÿ‡บ๐Ÿ‡ธ

Salt Lake City, Utah, United States

West Virginia University

๐Ÿ‡บ๐Ÿ‡ธ

Morgantown, West Virginia, United States

University of Miami

๐Ÿ‡บ๐Ÿ‡ธ

Miami, Florida, United States

Northwestern University

๐Ÿ‡บ๐Ÿ‡ธ

Chicago, Illinois, United States

Beth Israel Deaconess Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Boston, Massachusetts, United States

University of Washington

๐Ÿ‡บ๐Ÿ‡ธ

Seattle, Washington, United States

Wayne State University

๐Ÿ‡บ๐Ÿ‡ธ

Detroit, Michigan, United States

ยฉ Copyright 2025. All Rights Reserved by MedPath